# Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

> **NCT03828617** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1710 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 20vPnC
- **BIOLOGICAL:** 20vPnC
- **BIOLOGICAL:** 20vPnC
- **BIOLOGICAL:** 13vPnC

## Key facts

- **NCT ID:** NCT03828617
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-14
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 1710 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828617, "Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03828617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*